SEMA3E and uterine cancer: Interestingly, Chen et al. [26] evaluated Sema3E expression in prostate, mammary, ovarian, and uterine cancer, and found, in agreement with previous reports [5–8, 23], that Sema3E was overexpressed in these cancers.